Try our Advanced Search for more refined results

In Re: Celexa and Lexapro Marketing and Sales Practices Litigation

  1. December 15, 2014

    Forest Gets Some Relief In Lexapro Marketing MDL

    A Massachusetts federal judge has thrown out one suit and trimmed a state law claim from another in the ongoing multidistrict litigation accusing Forest Laboratories Inc. of marketing antidepressants Celexa and Lexapro for use on adolescents, even though the U.S. Food and Drug Administration had not approved them for that purpose. 

  2. March 14, 2014

    Forest Pays Up To $10M In MDL Over Celexa, Lexapro

    Forest Laboratories Inc. agreed to pay between $7.7 million and $10.4 million to settle multidistrict litigation accusing the drugmaker of misleading Missouri parents into buying Celexa and Lexapro for children although the drugs were only approved for adults, according to papers filed in Massachusetts federal court Thursday.

  3. January 13, 2014

    Forest Can't Nix Mo. Class In Antidepressant Marketing MDL

    A Massachusetts federal judge on Friday certified a class of Missouri parents accusing Forest Pharmaceuticals Inc. of misleading them into buying antidepressants for their children that were only approved for adults, but he refused to approve similar proposed classes of New York and Illinois consumers.

  4. February 05, 2013

    Judge Denies Class Cert. In Antidepressant Marketing MDL

    A Massachusetts federal judge denied class certification Tuesday in three coordinated lawsuits alleging Forest Pharmaceuticals Inc. illegally promoted antidepressants Celexa and Lexapro for use in children, saying plaintiffs in two cases didn't adequately represent their classes and another hadn't shown common issues predominated.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!